SINGAPORE-BASED biotech Cennerv Pharmaceuticals is making a second attempt at an initial public offering listing on the Singapore Exchange's Catalist board, with the lodging of a new preliminary offer document on Wednesday.The firm, which develops drugs to treat central nervous system disorders, first registered a preliminary prospectus for a planned listing in September last year.
For the nine months ended Sept 30, 2018, Cennerv's net loss widened by 48.2 per cent to S$1.84 million, versus a net loss of S$1.24 million in the year-ago period. This came on the back of an increase in employee compensation arising from consultancy expenses, and the payment of professional fees for the listing application, the company said.
According to the company's offer document, listing-related expenses accounted for about S$536,000 of its professional fees for the nine-month period in 2018, up from about S$108,000 in 2017.
Source: News Formal (newsformal.com)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Reclaims Global launches Catalist IPO at 23 S cents per shareECO-friendly construction service provider Reclaims Global launches on Friday its initial public offering (IPO) of 20 million shares at S$0.23 each. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »
Iron ore concentrate producer Fortress Minerals seeks Catalist listingFORTRESS Minerals Limited, an iron ore concentrate producer, has lodged a preliminary prospectus for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »
Sim Leisure Group debuts on Catalist at S$0.17 apiecePENANG theme park developer Sim Leisure Group (SLG) made its Catalist debut on the Singapore bourse on Friday, opening at S$0.17 apiece - 22.7 per cent lower than its initial public offering (IPO) price of S$0.22 per share. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »
Lyft IPO filing shows US$2.2 billion revenue as company looks to woo investors on growthLyft Inc inched closer to becoming the first ride-hailing company to make a stock market debut by releasing its filing for an initial public ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Lyft IPO filing shows surging revenue, widening lossesLyft Inc inched closer to becoming the first ride-hailing company to make a stock market debut by releasing its filing for an initial public ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Redeeming preference shares with IPO proceeds was priority from the start: Sim Leisure GroupINVESTORS in theme park operator Sim Leisure Group (SLG) will make known how they feel about the majority of its initial public offering (IPO) money going into redemption of S$5.6 million in preference shares, when it debuts on Friday. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »
With IPO due, Uber aims to be ‘Amazon of transportation’SANTA MONICA Uber, the ride-sharing behemoth set to launch a stock offering soon, is aiming beyond sharing car rides to becoming the 'Amazon of transportation' in a future where people share instead of owning vehicles. The California-based start-up laid out its vision of a...
Source: thenewpaper - 🏆 7. / 63 Read more »
Chinese drone maker EHang plans US IPO: SourcesHONG KONG: Chinese drone maker EHang is planning a US initial public offering (IPO) this year, according to two people with direct knowledge of ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
'Sharing economy' goes mainstream as IPOs loomThe 'sharing economy' is becoming mainstream with the anticipated stock listings from services such as Uber, Lyft and Airbnb, signs that the trend is gaining momentum and impacting multiple sectors. - In transportation, some analysts argue the sharing trend is moving at a breakneck pace that
Source: YahooSG - 🏆 3. / 71 Read more »
ImmunoGen's ovarian cancer drug fails in late-stage studyREUTERS: U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »